Skip NavigationSkip to Content
Return Return to Search Results

COVID-19 vaccine efficacy in participants with weakened immune systems from four randomized-controlled trials

  1. Author:
    Sherman, Amy [ORCID]
    Tuan, Jessica
    Cantos, Valeria D
    Adeyiga, Oladunni
    Mahoney, Scott
    Ortega-Villa, Ana M
    Tillman,Amy
    Whitaker, Jennifer
    Woodward Davis, Amanda S
    Leav, Brett
    Hirsch, Ian
    Sadoff, Jerald
    Dunkle, Lisa M
    Gilbert, Peter B
    Janes, Holly E
    Kublin, James G
    Goepfert, Paul A
    Kotloff, Karen
    Rouphael, Nadine
    Falsey, Ann R
    El Sahly, Hana M
    Sobieszczyk, Magdalena E
    Huang, Yunda
    Neuzil, Kathleen M
    Corey, Lawrence
    Grinsztejn, Beatriz
    Gray, Glenda
    Nason, Martha
    Baden, Lindsey R
    Gay, Cynthia L

  2. Author Address

    Brigham and Women's Hospital, Harvard Medical School, Department of Medicine, Division of Infectious Diseases, Boston, MA, USA., Yale School of Medicine, Section of Infectious Diseases, New Haven, CT, USA., Emory University, Division of Infectious Diseases, Atlanta, GA, USA., University of California, Los Angeles, Department of Medicine, Division of Infectious Diseases, Los Angeles, CA, USA., University of Cape Town, Desmond Tutu HIV Centre, Department of Medicine, Cape Town, South Africa., National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA., Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Baylor College of Medicine, Department of Molecular Virology and Microbiology and Section of Infectious Diseases, Department of Medicine, Houston, TX, USA., Fred Hutchinson Cancer Center, Vaccine and Infectious Disease Division, Seattle, WA, USA., Moderna Inc., Cambridge, MA, USA., Vaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK., Janssen Vaccines and Prevention, Leiden, Netherlands., Novavax, Gaithersburg, MD, USA., University of Alabama at Birmingham, Department of Medicine, Birmingham, AL, USA., University of Maryland School of Medicine, Department of Pediatrics and the Center for Vaccine Development and Global Health, Baltimore, MD, USA., Hope Clinic, Emory University, Atlanta, GA, USA., University of Rochester, Infectious Disease Division, Rochester, NY, USA., Columbia University Irving Medical Center, Department of Medicine, New York, NY, USA., University of Maryland School of Medicine, Center for Vaccine Development and Global Health, Baltimore, MD, USA., University of Washington, Department of Laboratory Medicine and Pathology, Seattle, WA, USA., National Institute of Infectious Diseases-Oswaldo Cruz Foundation, Rio de Janeiro, Brazil., University of the Witwatersrand, Perinatal HIV Research Unit, Faculty of Health Sciences, Johannesburg, South Africa; South African Medical Research Council, Cape Town, South Africa., National Institute of Allergy and Infectious Diseases, National Institutes of Health Bethesda, MD, USA., University of North Carolina at Chapel Hill School of Medicine, Department of Medicine, Division of Infectious Diseases, UNC HIV Cure Center, Chapel Hill, NC, USA.,
    1. Year: 2024
    2. Date: Apr 10
    3. Epub Date: 2024 04 10
  2. Journal: Clinical Infectious Diseases : an official publication of the Infectious Diseases Society of America
  4. Type of Article: Article
  5. Article Number: ciae192
  1. Abstract:

    Although the SARS-CoV-2 vaccines are highly efficacious at preventing severe disease in the general population, current data are lacking regarding vaccine efficacy (VE) for individuals with mild immunocompromising conditions. A post-hoc, cross-protocol analysis of participant-level data from the blinded phase of four randomized, placebo-controlled, COVID-19 vaccine phase 3 trials (Moderna, AstraZeneca, Janssen, and Novavax) was performed. We defined a "tempered immune system" (TIS) variable via a consensus panel based on medical history and medications to determine VE against symptomatic and severe COVID-19 cases in TIS participants versus non-TIS (NTIS) individuals starting at 14 days after completion of the primary series through the blinded phase for each of the four trials. An analysis of participants living with well-controlled HIV was conducted using the same methods. 3,852/30,351 (12.7%) Moderna participants, 3,088/29,868 (10.3%) Novavax participants, 3,549/32,380 (11.0%) AstraZeneca participants, and 5,047/43,788 (11.5%) Janssen participants were identified as having a TIS. Most TIS conditions (73.9%) were due to metabolism and nutritional disorders. Vaccination (versus placebo) significantly reduced the likelihood of symptomatic and severe COVID-19 for all participants for each trial. VE was not significantly different for TIS participants vs NTIS for either symptomatic or severe COVID-19 for each trial, nor was VE significantly different in the symptomatic endpoint for participants with HIV. For individuals with mildly immunocompromising conditions, there is no evidence of differences in VE against symptomatic or severe COVID-19 compared to those with non-tempered immune systems in the four COVID-19 vaccine randomized controlled efficacy trials. © The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.

    See More

  1. Keywords:

External Sources

  1. View Full Text
  2. DOI: 10.1093/cid/ciae192
  3. PMID: 38598658
  4. PII : 7643769

Library Notes

  1. Fiscal Year: FY2023-2024
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel